Form 4: Crinetics Pharmaceuticals Director Nichols Weston Reports Acquisition and Disposal of Shares

Director Nichols Weston reports acquiring 3,400 shares of Crinetics Pharmaceuticals common stock and disposing of 9,400 shares, along with receiving options to purchase 12,500 shares.

Summary

• On June 7, 2024, Nichols Weston, a director of Crinetics Pharmaceuticals, reported acquiring 3,400 shares of common stock at $0.
• On the same day, Weston disposed of 9,400 shares of common stock.
• Following these transactions, Weston beneficially owns 9,400 shares.
• Weston also acquired options to purchase 12,500 shares of common stock at an exercise price of $44.71, exercisable on the earlier of June 7, 2025, or the next annual meeting, expiring on June 7, 2034.
• The restricted stock units vest 100% on the earlier of the first anniversary of the grant date or the next occurring annual meeting of the Issuer's stockholders, subject to continued service on the board.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The acquisition of restricted stock units and options suggests confidence, but the disposal of shares tempers the overall outlook.

Positives

• The acquisition of restricted stock units and stock options by a director could be seen as a positive sign, indicating confidence in the company's future performance.

Negatives

• The disposal of 9,400 shares by the director could be interpreted negatively, although the acquisition of restricted stock units and options may offset this concern.

Risks

• The vesting of the restricted stock units and stock options is contingent upon the director's continued service on the board, creating a potential risk if the director were to leave the company.

Future Outlook

The vesting of the restricted stock units and stock options is tied to the director's continued service, suggesting an expectation of ongoing involvement and alignment with the company's future success.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. Monitoring these filings can offer insights into management's sentiment and expectations regarding the company's performance.

Comparison to Industry Standards

• Stock option grants and restricted stock units are common forms of executive compensation in the pharmaceutical industry, used to align management's interests with those of shareholders.
• The vesting schedules and exercise prices are generally in line with industry practices, designed to incentivize long-term value creation.

Stakeholder Impact

• The transactions may have a minor impact on shareholders, potentially influencing market perception of the company.
• The vesting conditions of the equity awards incentivize the director to remain engaged and contribute to the company's success, benefiting stakeholders.

Key Dates